Olanzapine And Samidorphan

Introduction Overview

Generic Name

olanzapine and samidorphan

Brand Name

Lybalvi

Dosage Form

oral tablet (5 mg/10 mg, 10 mg/10 mg, 15 mg/10 mg, 20 mg/10 mg)

Drug Class

Psychotherapeutic combinations

Pharmacokinetics

Absorption:
Lybalvi is administered as oral tablets combining olanzapine and samidorphan. Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations between 5 to 8 hours post-dose. Samidorphan is rapidly absorbed with peak plasma levels typically attained approximately 1 hour after administration. The presence of food has a minimal effect on the absorption of both drugs, allowing flexible dosing with or without meals. Clinical pharmacokinetic studies have shown consistent bioavailability across the various dose strengths formulated in Lybalvi.

Distribution:
Olanzapine exhibits a large volume of distribution (approximately 10-20 L/kg), indicating extensive tissue binding. It is moderately bound to plasma proteins (~93%). Samidorphan has a similar moderate plasma protein binding of approximately 69%. Both compounds readily cross the blood-brain barrier, enabling central nervous system activity essential for their therapeutic actions. Distribution may be influenced by patient variables such as age, body mass, and hepatic function; olanzapine’s lipophilicity facilitates its penetration into multiple tissue compartments.

Metabolism:
The metabolism of olanzapine primarily involves hepatic cytochrome P450 enzymes, mainly CYP1A2 and to a lesser extent CYP2D6, producing inactive metabolites. Smoking induces CYP1A2 and can enhance olanzapine metabolism, reducing plasma concentrations. Samidorphan undergoes hepatic metabolism primarily via CYP3A4 to inactive metabolites. Co-administration with CYP3A4 modulators can therefore influence samidorphan levels. Both agents exhibit linear pharmacokinetics over the therapeutic dosing range.

Elimination:
Olanzapine and its metabolites are primarily eliminated via hepatic routes into the urine and feces, with an elimination half-life ranging from approximately 21 to 54 hours in healthy adults, permitting once-daily dosing. Samidorphan has a shorter half-life, approximately 7 to 10 hours, but the combined formulation in Lybalvi allows for stable plasma concentrations when dosed once daily. Impaired hepatic or renal function may alter elimination clearance, necessitating careful monitoring. No significant accumulation is expected with repeated dosing at recommended doses.

Dosage Forms

Available Dosage Forms:
Lybalvi is formulated as oral film-coated tablets available in the following fixed-dose combinations of olanzapine and samidorphan:
- 5 mg olanzapine / 10 mg samidorphan
- 10 mg olanzapine / 10 mg samidorphan
- 15 mg olanzapine / 10 mg samidorphan
- 20 mg olanzapine / 10 mg samidorphan

Dosages for Adults and Adolescents:
Lybalvi is approved for use in adults to treat schizophrenia and manic or mixed episodes associated with bipolar I disorder. Dosing regimens vary based on indication and patient response:
- For schizophrenia: Starting doses typically 5/10 mg or 10/10 mg once daily, with maintenance doses ranging from 10/10 mg to 20/10 mg once daily.
- For bipolar I disorder (manic or mixed episodes): Starting doses of 10/10 mg or 15/10 mg once daily; maintenance doses between 5/10 mg to 20/10 mg daily.
- For bipolar I disorder with concomitant lithium or valproate therapy: Starting dose of 10/10 mg daily; maintenance doses up to 20/10 mg daily as tolerated.

Specific Patient Populations:
The safety and efficacy of Lybalvi in pediatric patients have not been established. There are no approved dosing recommendations for children. Dose adjustments in elderly patients should be cautious, especially considering increased sensitivity and risk of adverse events. Patients with hepatic or renal impairment require careful monitoring, although no formal dose adjustments are specified; clinical judgment is advised. Concomitant medications affecting CYP1A2 or CYP3A4 activity may necessitate dose evaluation. Pregnant or breastfeeding women should consult healthcare providers due to unknown safety profiles in these populations.

Mechanism Of Action

Lybalvi is a unique combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid receptor antagonist, designed to optimize therapeutic benefits while mitigating common adverse metabolic effects. Olanzapine primarily exerts its antipsychotic effects through antagonism at multiple neurotransmitter receptors in the central nervous system. It potently blocks dopamine D2 receptors, which helps to reduce hallucinations, delusions, and disorganized thinking commonly seen in schizophrenia and bipolar disorder. Olanzapine also antagonizes serotonin 5-HT2A, 5-HT2C, 5-HT3, and 5-HT6 receptors, which modulates mood, cognition, and other neuropsychiatric symptoms.

At the molecular level, olanzapine's broad receptor binding profile impacts dopaminergic, serotonergic, adrenergic, histaminergic, and muscarinic pathways. Its high affinity for histamine H1 and muscarinic receptors contributes to sedation and anticholinergic side effects, respectively. In clinical settings, this multi-receptor interaction is associated with efficacy in treating both positive and negative symptoms of schizophrenia as well as mood stabilization in bipolar disorder.

Samidorphan, the opioid antagonist component, selectively binds to mu-opioid receptors blocking endogenous opioid activity. This antagonism is thought to mitigate olanzapine-induced weight gain by modulating reward-related feeding behavior and reducing appetite enhancement mediated by the opioid system. Additionally, samidorphan’s blockade of opioid receptors in both central and peripheral tissues helps reduce metabolic dysregulation, a common adverse effect limiting olanzapine use. This mechanistic synergy is supported by clinical studies demonstrating reduced weight gain and metabolic effects when samidorphan is co-administered.

Clinical evidence indicates that the combination does not significantly impair olanzapine's antipsychotic efficacy while providing improved metabolic safety. Compared with other antipsychotic agents lacking opioid antagonism, Lybalvi represents an innovative therapeutic offering that addresses both psychiatric symptom control and metabolic side effect management. Ongoing research continues to explore the biochemical interactions underlying these effects and the potential benefits for long-term treatment adherence and outcomes.

Pharmacological Actions

Antagonism of dopamine D2 receptors to reduce psychotic symptoms such as hallucinations and delusions.
Blockade of multiple serotonin receptor subtypes (5-HT2A, 5-HT2C, 5-HT3, 5-HT6) improving mood and cognitive symptoms.
Antagonistic activity at histamine H1 receptors contributing to sedation and appetite modulation.
Muscarinic receptor antagonism leading to anticholinergic effects.
Mu-opioid receptor antagonism by samidorphan to counteract olanzapine-associated weight gain and metabolic side effects.
Modulation of central nervous system neurotransmitters involved in mood stabilization and psychosis control.
Reduction of reward-based feeding behavior through opioid receptor blockade.
Balancing therapeutic efficacy with adverse metabolic risk mitigation.
Pharmacodynamic synergy between atypical antipsychotic and opioid antagonist mechanisms.
Potential neuroprotective effects through multi-receptor pathway interaction.

Therapeutic Or Clinical Uses

Treatment of manic or mixed episodes associated with bipolar I disorder in adults, either as monotherapy or adjunctive to lithium or valproate.
Management of schizophrenia symptoms in adults, including hallucinations, delusions, and disorganized thinking.
Reduction of weight gain risk commonly associated with olanzapine therapy via opioid antagonism.
Use in adult patients requiring an atypical antipsychotic with a reduced metabolic side effect profile.
Potential use in mood stabilization within bipolar disorder treatments.
Treatment option when olanzapine is indicated but weight gain is a significant concern.
Adjunct therapy with mood stabilizers such as lithium or valproate in bipolar I disorder.
Management of psychosis with simultaneous consideration of metabolic risk factors.
Off-label considerations based on clinical judgment for related psychiatric conditions influenced by dopamine-serotonin dysregulation.
Part of comprehensive psychiatric treatment plans emphasizing balance between efficacy and quality of life.

Side Or Adverse Effects

Weight gain, observed in approximately 19-25% of patients during clinical trials.
Somnolence or sleepiness, potentially affecting daytime alertness.
Dry mouth, a common anticholinergic side effect.
Headache, reported as a frequent adverse event.
Weakness and dizziness, contributing to fall risk especially in elderly patients.
Constipation and increased appetite potentially related to olanzapine’s activity.
Shaking or tremor reported in some patients.
Back pain and mouth-watering observed particularly when used with lithium or valproate.
Memory impairment and problems with speech noted in some clinical scenarios.
Numbness and tingling sensations in extremities (paresthesia).
Neuroleptic malignant syndrome (NMS), a rare but potentially fatal reaction.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), which can be life-threatening.
Metabolic abnormalities including hyperglycemia, diabetes, increased cholesterol and triglycerides.
Tardive dyskinesia characterized by involuntary, persistent movements.
Orthostatic hypotension causing fainting and increased fall risk.
Low white blood cell count necessitating regular hematologic monitoring.
Difficulty swallowing increasing risk of aspiration pneumonia.
Seizures (convulsions) in predisposed individuals.
Problems with thermoregulation leading to heat intolerance.

Precautions

Do not use in patients currently taking opioids or experiencing acute opioid withdrawal.
Monitor blood glucose regularly due to risk of hyperglycemia and diabetes.
Frequent assessment of lipid profiles (cholesterol and triglycerides) is recommended.
Evaluate and monitor for signs of tardive dyskinesia throughout treatment.
Careful monitoring of white blood cell counts during initial months of therapy.
Avoid use in elderly patients with dementia-related psychosis owing to increased mortality risk.
Assess for risk factors of orthostatic hypotension; advise patients to rise slowly from sitting or lying positions.
Caution in patients with a history of seizures; monitor for seizure activity.
Use cautiously in patients with swallowing difficulties to prevent aspiration.
Avoid concomitant administration with other olanzapine-containing products to prevent overdose.
Patients should avoid alcohol consumption during therapy.
Monitor prolactin levels as increases have been reported.
Exercise caution in patients with cardiovascular disease or history of stroke.
Consider potential for sedation impacting activities requiring alertness such as driving.
Advise patients about heat intolerance and risk of dehydration; encourage adequate hydration.
Inform patients about the risk of false positive opioid urine drug screens.
Pregnant and breastfeeding women should consult healthcare providers before use.
Assess renal and hepatic function prior to and during treatment for dose adjustment considerations.

Warnings

Boxed Warning: Increased risk of death in elderly patients with dementia-related psychosis; Lybalvi is not approved for treatment of dementia-related psychosis.
Risk of cerebrovascular adverse events (stroke) in elderly patients with dementia-related psychosis.
Potential for severe and life-threatening opioid withdrawal if Lybalvi is administered to physically dependent opioid users.
Risk of life-threatening opioid overdose if opioids are administered during or shortly after stopping Lybalvi; opioid sensitivity is increased after theraoy.
Neuroleptic malignant syndrome (NMS) characterized by high fever, muscle rigidity, autonomic instability, and altered mental status.
Fatal Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) reported with olanzapine.
Metabolic disturbances including hyperglycemia and diabetic ketoacidosis; regular metabolic monitoring is essential.
Tardive dyskinesia which may be irreversible and can appear during or after discontinuation of treatment.
Orthostatic hypotension with potential for syncope and falls.
Increased prolactin levels with potential reproductive and endocrine effects.
Seizure risk, particularly in patients with predisposing factors.
Potential for impaired thermoregulation leading to heat stroke.
Potential for significant sedation and impaired cognitive or motor performance.
Risk of low white blood cell count causing increased susceptibility to infections.
Patients should be monitored for swallowing difficulties leading to aspiration pneumonia.

Contraindication

Concurrent use with opioids or in patients currently physically dependent on opioids due to risk of withdrawal.
Known hypersensitivity to olanzapine, samidorphan, or any inactive ingredients in Lybalvi.
Patients with dementia-related psychosis owing to increased mortality risk.
History of severe allergic reactions or anaphylaxis to components of the formulation.
Use with other olanzapine-containing medications to avoid additive toxicity.
Acute opioid withdrawal states; initiation of Lybalvi during these periods is contraindicated.
Severe hepatic impairment where metabolism could be substantially altered and increase toxicity risk.
Patients with known hypersensitivity to opioid antagonists such as samidorphan.
Use should be avoided in individuals for whom oral administration is contraindicated or unsafe.
Off-label contraindications may apply per clinical discretion based on patient-specific factors.

Drug Interactions

Concomitant use with opioids is contraindicated due to risk of opioid withdrawal syndrome and reduced opioid efficacy.
CYP1A2 inducers (e.g., smoking) can decrease olanzapine plasma concentrations, potentially reducing efficacy.
CYP3A4 inhibitors or inducers may alter samidorphan metabolism, affecting plasma levels and clinical effects.
Co-administration with CNS depressants, including alcohol and benzodiazepines, may enhance sedation and respiratory depression.
Other antipsychotics or CNS-active drugs may have additive side effects including sedation, hypotension, and metabolic disturbances.
Medications prolonging QT interval may increase arrhythmia risk when combined with olanzapine.
Drugs that affect glucose metabolism may interact adversely with Lybalvi’s metabolic side effects.
Concomitant lithium or valproate use requires monitoring due to potential pharmacodynamic interactions and side effect profile changes.
Potential pharmacokinetic interactions with drugs altering hepatic enzyme activity necessitate careful dose adjustment and monitoring.
Interactions with drugs that affect prolactin levels may compound endocrine side effects.
Lybalvi may cause false positive opioid urine drug screening tests, affecting clinical monitoring.
Caution when combined with antihypertensive agents due to additive hypotensive effects.
Use with drugs that affect thermoregulation can increase risk of heat-related adverse events.
Interaction with seizure threshold lowering drugs increases risk of convulsions.
Potential interaction with anticholinergic agents may exacerbate anticholinergic adverse effects.

Preparations Of The Drug

Lybalvi comes as oral film-coated tablets.
Available fixed-dose combination tablets with olanzapine/samidorphan in 5 mg/10 mg, 10 mg/10 mg, 15 mg/10 mg, and 20 mg/10 mg strengths.
Inactive ingredients include colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, and microcrystalline cellulose.
Film coating ingredients vary by dosage strength and include hypromellose, titanium dioxide, triacetin, and colorants such as iron oxide yellow, iron oxide red, and FD&C Blue No. 2/indigo carmine aluminum lake.
Tablets are intended to be swallowed whole; not to be split or combined.
Stored at controlled room temperature between 68°F to 77°F (20°C to 25°C).
Maintained in tightly closed containers to protect from moisture and degradation.
Packaged to minimize exposure to light and environmental factors.
Supplied in blister packs or bottles as per manufacturer specifications.
Distributed exclusively by Alkermes, Inc., produced in specialized manufacturing facilities compliant with Good Manufacturing Practice standards.
No generic equivalents currently available; only branded preparation marketed.
Labeling includes detailed prescribing information, warnings, and patient counseling guidelines.
Patient education materials are provided to inform about proper administration and side effect management.
Handling and disposal recommendations align with pharmaceutical safety standards.
Lot and batch numbers detailed on packaging for traceability.